journal article·2013-08

Clay–polymer nanocomposites as a novel drug carrier: Synthesis, characterization and controlled release study of Propranolol Hydrochloride

Seema, Monika Datta

Applied Clay Science· Volume 80-81
Publisher page

Abstract

Abstract Short half life of Propranolol Hydrochloride (PPN), an antihypertensive drug is a prime requirement to develop a formulation which could extend the release of PPN in the human body and also eliminate daily multiple dosage of PPN. In this study, a system of PPN loaded Montmorillonite–Poly lactic-co-glycolic acid (Mt–PLGA) nanocomposites has been developed. PPN incorporated PLGA nanoparticles have been compared with Mt–PPN–PLGA nanocomposites. Mt was used as sustained release carrier for PPN with addition of biodegradable polymer PLGA by preparing Mt–PPN–PLGA nanocomposites by double emulsion solvent evaporation method. The drug encapsulation efficiency and drug loading capacity of synthesized products were estimated with HPLC including suitable analytical techniques to confirm the formation of clay–polymer nanocomposites (CPN). The release profile of encapsulated PPN in CPN shows pH dependent release in simulated gastrointestinal fluid for a period of 8 h. This study suggests that the methodologies used are suitable for the synthesis of Mt based PLGA nanocomposites with high drug encapsulation efficiency and controlled drug release characteristics and indicates that the Mt–PPN–PLGA nanocomposites are supposed to be better oral controlled drug delivery system, for a highly hydrophilic low molecular weight antihypertensive drug PPN to minimize the drug dosing frequency and hence improving the patient compliance.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Clay minerals and soil interactions · Polymer Nanocomposites and Properties · Layered Double Hydroxides Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (34)

Show source-provided references
1. Use of clays as drug delivery systems: possibilities and limitations10.1016/j.clay.2006.06.015 ↗
2. Bergaya · 2006
3. Floating matrix dosage form for propranolol hydrochloride based on gas formation technique: development and in vitro evaluation10.3797/scipharm.0909-02 ↗
4. Tramadol hydrochloride/montmorillonite composite: Preparation and controlled drug release10.1016/j.clay.2010.04.011 ↗
5. Dollery · 1991 · P272
6. Poly (d, l-lactide-co-lycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs10.1016/j.biomaterials.2005.03.021 ↗
7. Simultaneous high-performance liquid chromatographic assay of furosemide and propranolol HCL and its application in a pharmacokinetic study10.1016/S0731-7085(03)00229-2 ↗
8. Poly(lactide)–vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel10.1016/j.biomaterials.2009.02.045 ↗
9. Development and optimization of a novel sustained-release dextran tablet formulation for propranolol hydrochloride10.1016/j.ijpharm.2006.02.049 ↗
10. Hybrid materials based on montmorillonite and citostatic drugs: preparation and characterization10.1016/j.clay.2011.01.031 ↗
11. Montmorillonite as a drug delivery system: intercalation and in vitro release of Timolol maleate10.1016/j.ijpharm.2009.03.004 ↗
12. Montmorillonite intercalated with Vitamin B1 as drug carrier10.1016/j.clay.2009.06.001 ↗
13. Design and evaluation of controlled drug delivery system of buspirone using inorganic layered clay mineral10.1016/j.micromeso.2010.04.003 ↗
14. Intercalation of amido cationic drug with montmorillonite
15. Polymeric systems for controlled drug release10.1021/cr940351u ↗
16. Toxicity assessment of montmorillonite as a drug carrier for pharmaceutical applications: yeast and rats model10.4015/S1016237205000111 ↗
17. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier10.1016/S0142-9612(01)00325-8 ↗
18. Intercalation and exfoliation: a review on morphology of polymer nanocomposites reinforced by inorganic layer structures10.1080/AMP-200068646 ↗
19. An approach to controlled-release dosage form of propranolol hydrochloride10.1081/DDC-100100332 ↗
20. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy
21. Loading and delivery of sertraline using inorganic micro and mesoporous materials10.1016/j.ejpb.2006.11.023 ↗
22. Pellet characteristics and drug release when the form of propranolol is fixed as moles or mass in formulations for extruded and spheronized Carbopol-containing pellets10.1016/j.ijpharm.2008.11.002 ↗
23. Formulation and evaluation of propranolol hydrochloride-loaded carbopol-934p/ethyl cellulose mucoadhesive microspheres
24. Design and evaluation of sustained release bilayer tablets of propranolol hydrochloride10.2478/v10007-007-0038-0 ↗
25. Polymer nanotechnology: nanocomposites10.1016/j.polymer.2008.04.017 ↗
26. Propranolol–magnesium aluminum silicate complex dispersions and particles: characterization and factors influencing drug release10.1016/j.ijpharm.2009.09.016 ↗
27. Comparative study of propranolol hydrochloride release from matrix tablets with Kollidon®SR or hydroxy propyl methyl cellulose10.1208/s12249-008-9092-2 ↗
28. Interaction of propranolol hydrochloride with montmorillonite10.1111/j.2042-7158.1981.tb13821.x ↗
29. Matrix tablets of propranolol hydrochloride
30. A review of block polymer surfactants10.1007/BF02894385 ↗
31. Adsorption of promethazine hydrochloride with KSF montmorillonite10.1007/s10450-006-0141-4 ↗
32. Nanoclay drug delivery system
33. Dissolution kinetics evaluation of controlled-release tablets containing propranolol hydrochloride10.1081/DDC-100102205 ↗
34. Solubility, metastable zone width and racemic character of Propranolol hydrochloride10.1002/chir.10049 ↗